Practice guidelines for the therapy of primary myelodysplastic syndromes: A note of caution about their translation into clinical practice

Haematologica

Volumn 87, Issue 12, 2002, Pages 1240-1241

  Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG INDICATION; DRUG RESPONSE; DRUG USE; EDITORIAL; HUMAN; MEDICAL DECISION MAKING; MEDICAL RECORD; MEDICAL SOCIETY; MYELODYSPLASTIC SYNDROME; PATIENT REFERRAL; PRACTICE GUIDELINE; PUBLICATION; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

DECISION MAKING; HUMANS; MYELODYSPLASTIC SYNDROMES; ONLINE SYSTEMS; PRACTICE GUIDELINES;

EID: 0036902994     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Fabris F, Luzzatto G, Stefani PM, Girolami B, Cella G, Girolami A. Heparin-induced thrombocytopenia. Haematologica 2000; 85:72-81.
2. Burgio GR, Locatelli F. Alternative therapies and the Di Bella affair in pediatrics. A questionnaire submitted to Italian pediatric oncologists and hematologists. Haematologica 2000; 85:189-94.
3. Rock G, Porta C, Bobbio-Pallavicini E. Thrombotic thrombocytopenic purpura treatment in year 2000. Haematologica 2000; 85:410-9.
4. Dini G, Cancedda R, Locatelli F, Bosi A, Bandini G, Alessandrino EP, et al. Unrelated donor marrow transplantation: An update of the experience of the Italian Bone Marrow Group (GITMO). Haematologica 2001; 86:451-6.
5. Alessandrino EP, Amadori S, Barosi G, Cazzola M, Grossi A, Liberato LN, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87:1286-306.
6. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998; 83:910-35.
7. Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 2000; 85:367-71.
8. Musto P, Sanpaolo G, D'Arena G, Scalzulli PR, Matera R, Falcone A, et al. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Haematologica 2001; 86:44-51.
9. Ferrara F, Morabito F, Latagliata R, Martino B, Annunziata M, Oliva E, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica 2001; 86:814-20.
10. Bernasconi C. Evidence-based approach to treatment of myelodysplastic syndromes. Haematologica 2001; 86:897-9.
11. Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, et al. Myelodysplastic syndromes: Recent advances. Haematologica 2001; 86:1124-57.
12. Petti MC, Latagliata R, Breccia M, Alimena G, Spadea A, D'Andrea M, et al. Spontaneous remission in adult patients with de novo myelodysplastic syndrome: a possible event. Haematologica 2001; 86:1277-80.
13. Kassirer JP, Campion EW. Peer review. Crude and under-studied, but indispensable. JAMA 1994; 272:96-7.
14. Anonymous. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998; 103:1070-4.
15. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20:4083-107.
16. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346:469-75.